Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

CONCLUSION: Extended treatment with darolutamide was well tolerated and no new safety signals were observed. Most ARi-associated and androgen-suppressive treatment-related TEAEs occurred at low incidences with darolutamide, were similar to placebo, and showed minimal increase over time with continued treatment.TRIAL NUMBER: ClinicalTrials.gov identifier NCT02200614.PMID:38394384 | DOI:10.1093/oncolo/oyae019

Source: The Oncologist - February 23, 2024 Category: Cancer & Oncology Authors: Neal D Shore Christian Gratzke Susan Feyerabend Patrick Werbrouck Joan Carles Egils Vjaters Teuvo L J Tammela David Morris Jeanny B Aragon-Ching Raoul S Concepcion Urban Emmenegger Neil Fleshner Markus Grabbert Vilnis Lietuvietis Hakim Mahammedi Felipe M Source Type: research